Entries by Organicell

,

Organicell Starts Enrolling Long COVID Trial

MIAMI, FL / ACCESSWIRE / November 17, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB: OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative biological therapeutics and regenerative medicine, is pleased to announce that the long COVID Clinical Trial is officially active with enrollment.  “This announcement is an obligatory update because there has been a change […]

,

Organicell Activates COPD Trial at Mayo Clinic

DAVIE, FL / ACCESSWIRE / November 15, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative biological therapeutics and regenerative medicine, is pleased to announce that Mayo Clinic will be the site for clinical trials on Chronic Obstructive Pulmonary Disease (COPD).  Mayo Clinic in Phoenix, Arizona will be the […]

,

Organicell Regenerative Medicine, Inc. Announces Additions to Board of Directors

Expanded Board of Director Broadens Company’s Access to Valued Business Expertise and Relationships MIAMI, FL / ACCESSWIRE / October 11, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative biological therapeutics and regenerative medicine, announced that the Company has added independent board members to its board of directors. […]

,

Organicell Regenerative Medicine, Inc. Announces Expansion of Management Team

MIAMI, FL / ACCESSWIRE / September 20, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative biological therapeutics and regenerative medicine, announced that the Company has recruited a new Chief Operating Officer, Chief Information Officer, and Director of Finance. Organicell’s new Chief Operating Officer, Ryan Likes, has previously […]

,

Organicell Regenerative Medicine, Inc. Announces Expansion into Health and Beauty Market

MIAMI, FL / ACCESSWIRE / September 16, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative biological therapeutics and regenerative medicine, announced today that the Company will expand into the skincare and haircare industries. On September 14, 2022 BeautyHealth’s Hydrafacial (NASDAQ:SKIN) announced its new partnership with Organicell to […]

Organicell Featured on NewBeauty: Hydrafacial Launches Anti-Aging Exosome Booster to Target Inflammation

“Announced today, Hydrafacial is rolling out a first-of-its kind exosome booster in collaboration with biotech company Organicell to address cellular inflammation. Set to launch early next year, the brand says the booster will leverage “Organicell’s novel exosome technology based on regenerative technology that will address signs of aging and inflammation unlike anything else on the market.”” Read […]

,

BeautyHealth’s Hydrafacial Announces Partnership with Organicell to Develop Breakthrough Exosome Booster

Co-Created with Organicell, the first-to-market booster will address aging and inflammation through regenerative technology LONG BEACH, Calif., September 14, 2022–(BUSINESS WIRE)–The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial, today announced a collaboration with biotech company Organicell to co-create a first-to-market exosome booster that will address signs of aging and inflammation in the skin. […]

,

Organicell Regenerative Medicine, Inc. Secures Additional $11 Million in Financing in Preparation for Clinical Trial Enrollment

MIAMI, FL / ACCESSWIRE / September 9, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative biological therapeutics and regenerative medicine, has closed on an additional $1 million private stock purchase at $0.04 per share and secured a $10 Million Equity Line of Credit with Tysadco Partners, LLC. This […]

,

Organicell Regenerative Medicine, Inc. Engages Law Firm McDermott Will & Emery

MIAMI, FL / ACCESSWIRE / August 30, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company principally focused on the development of innovative regenerative medicine and biological therapeutics, announced today the broad-based engagement of top international law firm McDermott Will & Emery, widely considered to have the best health care practice in the nation. Organicell, […]